HRP20191516T1 - Farmaceutski pripravci koji sadrže natrij-nitrit - Google Patents
Farmaceutski pripravci koji sadrže natrij-nitrit Download PDFInfo
- Publication number
- HRP20191516T1 HRP20191516T1 HRP20191516T HRP20191516T1 HR P20191516 T1 HRP20191516 T1 HR P20191516T1 HR P20191516 T HRP20191516 T HR P20191516T HR P20191516 T1 HRP20191516 T1 HR P20191516T1
- Authority
- HR
- Croatia
- Prior art keywords
- sodium nitrite
- ppm
- sodium
- weight
- pharmaceutical preparation
- Prior art date
Links
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 title claims 40
- 235000010288 sodium nitrite Nutrition 0.000 title claims 20
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 208000029039 cyanide poisoning Diseases 0.000 claims 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 206010011409 Cross infection Diseases 0.000 claims 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004737 colorimetric analysis Methods 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 1
- 229910052753 mercury Inorganic materials 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 235000010344 sodium nitrate Nutrition 0.000 claims 1
- 239000004317 sodium nitrate Substances 0.000 claims 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims 1
- 235000019345 sodium thiosulphate Nutrition 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B21/00—Nitrogen; Compounds thereof
- C01B21/20—Nitrogen oxides; Oxyacids of nitrogen; Salts thereof
- C01B21/50—Nitrous acid; Salts thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/204998—Inorganic carbon compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (10)
1. Natrijev nitrit koji sadrži ne više od 0,02 mas.% natrijevog karbonata i ne veći od 10 ppm sredstva protiv zgrudnjavanja,
pri čemu natrijev nitrit ima gubitak od sušenja ne veći od 0,25 tež%;
pri čemu sadržaj vode u natrijevom nitritu nije veći od 0,5 tež%;
pri čemu natrijev nitrit sadrži ne više od 0,4 tež.% natrij nitrata, ne više od 0,005 tež% netopljivih tvari, ne više od 0,005 tež% klorida, ne više od 0,01 tež% sulfata, ne više od 0,001 mas.% željeza, ne više od 0,01 tež% kalcija, ne više od 0,005 mas.% kalija, ne više od 0,05 ppm žive, ne više od 2 ppm aluminija, ne više od 3 ppm arsena i ne više od 0,003 tež% selena;
pri čemu natrijev nitrit ne sadrži više od 10 ppm, ne više od 100 ppm, ne više od 500 ppm, ne više od 1000 ppm, ili ne više od 5000 ppm organskih hlapljivih nečistoća;
pri čemu ukupni sadržaj nehlapljivog organskog ugljika u natrijevom nitritu nije veći od 2,5 ppm ili nije veći od 10 ppm;
pri čemu natrijev nitrit ima ukupan aerobni broj mikrobnog opterećenja ne veći od 100 CFU/g, u kupni broj kvasca i plijesni nije veći od 20 CFU/g, ne sadrži više od 0,25 EU/mg bakterijskih endotoksina;
pri čemu natrijev nitrit sadrži najmanje 97 tež% i ne više od 101 tež% natrijevog nitrita, mjereno USP kolormetrijskim testom; i
pri čemu sadržaj teških metala u natrijevom nitritu nije veći od 10 ppm.
2. Farmaceutski pripravak, naznačen time da sadrži natrijev nitrit iz zahtjeva 1 i jedan ili više farmaceutski prihvatljivih nosača ili pomoćnih sredstava.
3. Farmaceutski pripravak prema zahtjevu 2, naznačen time, što je pripravak za oralnu, parenteralnu, inhalacijsku, nazalnu, intravezikalnu, vaginalnu, rektalnu, sublingvalnu, oftalmičku ili topičku primjenu.
4. Farmaceutski pripravak prema zahtjevu 3, naznačen time, što je pripravak formuliran kao oblik pojedinačne doze.
5. Farmaceutski pripravak prema bilo kojem od zahtjeva 2 do 4, naznačen time, da je farmaceutski prihvatljiva pomoćna tvar voda.
6. Postupak za pripremu farmaceutski prihvatljivog natrijevog nitrita iz zahtjeva 1, naznačen time da sadrži sljedeće korake:
(a) kontakta natrijevog nitrita s vodom pri prvoj temperaturi od 45 do 55 ° C u inertnoj atmosferi;
(b) hlađenje otopine do druge temperature od 20 ° C do 30 ° C;
(c) kontakta vode koja sadrži natrijev nitrit s aktivnim ugljenom;
(d) kontakta smjese s etilnim alkoholom; i
(e) stvaranje natrijevog nitrita na trećoj temperaturi od 0 ° C do 10 ° C u inertnoj atmosferi.
7. Natrijev nitrit iz zahtjeva 1, naznačen time da se upotrebljava u postupku liječenja kardiovaskularne bolesti, respiratorne bolesti, kožne bolesti, trovanja cijanidom ili trovanja vodikovim sulfidom.
8. Natrijev nitrit za uporabu u postupku liječenja trovanja cijanidom prema zahtjevu 7, naznačen time da postupak nadalje uključuje primjenu natrijevog tiosulfata.
9. Natrijev nitrit iz zahtjeva 1, naznačen time, da se upotrebljava u postupku liječenja, sprečavanja i smanjenja rizika od infekcije bolnice.
10. Natrijev nitrit iz zahtjeva 1, naznačen time da je namijenjen uporabi u postupku poticanja rasta novih krvnih žila.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15182009P | 2009-02-11 | 2009-02-11 | |
US22402109P | 2009-07-08 | 2009-07-08 | |
EP10741692.7A EP2395834B1 (en) | 2009-02-11 | 2010-02-11 | Sodium nitrite-containing pharmaceutical compositions |
PCT/US2010/023824 WO2010093746A1 (en) | 2009-02-11 | 2010-02-11 | Sodium nitrite-containing pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191516T1 true HRP20191516T1 (hr) | 2019-11-29 |
Family
ID=42540617
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191516 HRP20191516T1 (hr) | 2009-02-11 | 2019-08-22 | Farmaceutski pripravci koji sadrže natrij-nitrit |
HRP20211077TT HRP20211077T1 (hr) | 2009-02-11 | 2021-07-06 | Farmaceutski pripravci koji sadrže natrij-nitrit |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211077TT HRP20211077T1 (hr) | 2009-02-11 | 2021-07-06 | Farmaceutski pripravci koji sadrže natrij-nitrit |
Country Status (15)
Country | Link |
---|---|
US (13) | US8568793B2 (hr) |
EP (3) | EP3862007A1 (hr) |
JP (2) | JP5789519B2 (hr) |
AU (1) | AU2010213743C1 (hr) |
CA (1) | CA2752129C (hr) |
CY (2) | CY1121939T1 (hr) |
DK (2) | DK3569237T3 (hr) |
ES (2) | ES2743303T3 (hr) |
HR (2) | HRP20191516T1 (hr) |
HU (2) | HUE055250T2 (hr) |
LT (2) | LT2395834T (hr) |
PL (2) | PL3569237T3 (hr) |
PT (2) | PT2395834T (hr) |
SI (2) | SI2395834T1 (hr) |
WO (1) | WO2010093746A1 (hr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004255268B2 (en) | 2003-07-09 | 2010-04-01 | Loma Linda University | Use of nitrite salts for the treatment of cardiovascular conditions |
CN101939014B (zh) | 2007-11-15 | 2016-04-27 | 路易斯安那州大学及农业和机械学院管理委员会 | 亚硝酸盐在慢性缺血中的应用 |
JP2011507968A (ja) * | 2007-12-27 | 2011-03-10 | エイヤーズ ファーマシューティカルズ、インク. | エアロゾル化ニトライトおよび一酸化窒素供与性化合物ならびにそれらの使用 |
US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
WO2010147742A2 (en) | 2009-06-18 | 2010-12-23 | Theravasc Inc. | Use of nitrite salts in treating tissue damage |
NO2451435T3 (hr) | 2009-07-08 | 2018-03-31 | ||
US20130209584A1 (en) * | 2009-10-14 | 2013-08-15 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
CN107260756A (zh) | 2009-10-14 | 2017-10-20 | 瑟阿瓦斯克有限公司 | 亚硝酸盐/酯的药物制剂以及其应用 |
US20140127329A1 (en) * | 2011-03-31 | 2014-05-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline |
CN102565230B (zh) * | 2012-01-09 | 2013-12-11 | 山东大学 | 一种聚异丁烯中游离氯离子的检测方法 |
ES2741146T3 (es) | 2013-02-20 | 2020-02-10 | The Board Of Supervisors Of The Louisiana State Univ Mechanical And Agricultural College | Formulaciones farmacéuticas de nitrio y sus usos |
WO2015168322A1 (en) * | 2014-04-29 | 2015-11-05 | Douglas Seals | Methods for treatment of motor and cognitive functions using sodium nitrite |
GB201602959D0 (en) | 2016-02-19 | 2016-04-06 | Isis Innovation | Use of cerebral nitric oxide donors in the assessment of the extent of brain dyfunction following injury |
CN106268664A (zh) * | 2016-08-28 | 2017-01-04 | 铜仁市万山区盛和矿业有限责任公司 | 一种含汞废水的处理剂及其制备方法 |
NZ756701A (en) | 2017-03-08 | 2022-07-01 | Hope Medical Entpr Inc Dba Hope Pharmaceuticals | Intradialytic use of sodium nitrite |
AU2018231072B2 (en) | 2017-03-08 | 2024-04-04 | Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals | Intradialytic use of sodium thiosulfate |
WO2019157295A1 (en) * | 2018-02-09 | 2019-08-15 | The Trustees Of Columbia University In The City Of New York | Treating infections using inhibitor of cbb3-type oxidases |
CN111989068A (zh) | 2018-05-24 | 2020-11-24 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
EP3801462A4 (en) | 2018-05-24 | 2022-03-16 | Celanese EVA Performance Polymers LLC | IMPLANTABLE DEVICE FOR EXTENDED RELEASE OF A MACROMOLECULAR DRUG COMPOUND |
JP2023510661A (ja) | 2019-06-04 | 2023-03-15 | サーティー ホールディングス リミテッド | 窒素酸化物を生成するための方法及び組成物、並びにそれらの使用 |
WO2020245574A1 (en) | 2019-06-04 | 2020-12-10 | Thirty Respiratory Limited | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract |
GB2610721A (en) | 2020-04-23 | 2023-03-15 | Thirty Respiratory Ltd | Methods and compositions for treating and combatting tuberculosis |
GB2610722A (en) | 2020-04-23 | 2023-03-15 | Thirty Respiratory Ltd | Nitric oxide or nitric oxide releasing compositions for use in treating SARS-COV and SARS-COV-2 |
WO2022049555A1 (en) * | 2020-09-07 | 2022-03-10 | Deepak Nitrite Limited | A free-flowing food grade sodium nitrite and production method thereof |
GB202101543D0 (en) | 2021-02-04 | 2021-03-24 | Thirty Respiratory Ltd | Vaping e-liquid composition and the use thereof |
WO2023118841A2 (en) | 2021-12-22 | 2023-06-29 | Thirty Holdings Limited | Powder composition |
WO2023118839A1 (en) | 2021-12-22 | 2023-06-29 | Thirty Holdings Limited | Powder composition |
US20230248677A1 (en) * | 2022-02-08 | 2023-08-10 | Visolis Technologies, Inc. | Novel highly sustainable compositions for modulation of gene expression in human skin, and methods of production thereof |
GB202215521D0 (en) | 2022-10-20 | 2022-12-07 | Thirty Holdings Ltd | Wound dressings |
GB202215758D0 (en) | 2022-10-25 | 2022-12-07 | Thirty Holdings Ltd | Implantable medical devices |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2032699A (en) * | 1932-07-23 | 1936-03-03 | Solvay Process Co | Process for the production of sodium nitrite |
NL203871A (hr) | 1955-02-09 | 1900-01-01 | ||
US2933377A (en) * | 1956-08-01 | 1960-04-19 | Du Pont | Process for making non-caking and free-flowing sodium nitrite |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3958941A (en) * | 1975-02-06 | 1976-05-25 | Sybron Corporation | Apparatus for measuring content of organic carbon |
US3965247A (en) * | 1975-06-20 | 1976-06-22 | Allied Chemical Corporation | Recovery of sodium nitrite from by-product process liquors containing sodium chloride |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4543190A (en) | 1980-05-08 | 1985-09-24 | Modar, Inc. | Processing methods for the oxidation of organics in supercritical water |
US4292311A (en) * | 1980-12-23 | 1981-09-29 | Sarnoff Stanley J | Cyanide antidote |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
USH1126H (en) * | 1991-11-12 | 1993-01-05 | The United States Of America As Represented By The Secretary Of The Navy | Treatment of sodium nitrite-containing boiler wastewater |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5405533A (en) | 1993-04-07 | 1995-04-11 | General Atomics | Heat transfer via dense gas in a fluid circulation system |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
US5387398A (en) | 1993-12-03 | 1995-02-07 | Aerojet General Corporation | Supercritical water oxidation reactor with wall conduits for boundary flow control |
US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
US5501799A (en) | 1994-06-07 | 1996-03-26 | Abitibi-Price, Inc. | Method to remove inorganic scale from a supercritical water oxidation reactor |
US6056883A (en) | 1994-06-07 | 2000-05-02 | Abitibi Consolidated Inc. | Method and apparatus to remove inorganic scale from a supercritical water oxidation reactor |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
ATE268591T1 (de) | 1995-06-27 | 2004-06-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US5804066A (en) | 1996-02-08 | 1998-09-08 | Aerojet-General Corporation | Injector for SCWO reactor |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
CN1233954A (zh) | 1996-10-01 | 1999-11-03 | 西马实验室股份有限公司 | 掩盖味道的微胶囊组合物及其制备方法 |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
ATE233088T1 (de) | 1996-12-20 | 2003-03-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US6054057A (en) | 1997-09-26 | 2000-04-25 | General Atomics | Downflow hydrothermal treatment |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6251354B1 (en) * | 1999-04-02 | 2001-06-26 | General Electric Co. | Process for recovering sodium nitrite |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
US6238568B1 (en) | 1999-05-06 | 2001-05-29 | General Atomics | Hydrothermal processing with phosphate additive |
AU2001276608A1 (en) | 2000-08-30 | 2002-03-13 | Pfizer Products Inc. | Sustained release formulations for growth hormone secretagogues |
GB0022084D0 (en) * | 2000-09-08 | 2000-10-25 | Univ Aberdeen | Treatment of multiply antibiotic-resistant organisms |
US6576185B2 (en) | 2000-12-28 | 2003-06-10 | General Atomics | System and method for hydrothermal reactions-three layer liner |
US6709602B2 (en) | 2001-04-23 | 2004-03-23 | General Atomics | Process for hydrothermal treatment of materials |
US6519926B2 (en) | 2001-05-01 | 2003-02-18 | General Atomics | Hydrothermal conversion and separation |
US6773581B2 (en) | 2001-10-18 | 2004-08-10 | General Atomics | System and method for solids transport in hydrothermal processes |
GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
US6855306B2 (en) * | 2002-09-26 | 2005-02-15 | General Chemical Performance Products Llc | Process for the recovery of sodium nitrite |
EP1576150A4 (en) * | 2002-10-16 | 2006-05-03 | Univ Texas | METHODS AND COMPOSITIONS FOR INCREASING THE EFFICACY OF ACTIVE SUBSTANCES FROM A BIOLOGICAL VIEWPOINT |
AU2004255268B2 (en) * | 2003-07-09 | 2010-04-01 | Loma Linda University | Use of nitrite salts for the treatment of cardiovascular conditions |
US20080069779A1 (en) * | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
KR20070003815A (ko) * | 2003-12-15 | 2007-01-05 | 니트리케어 에이취비 | 치료제 투여 장치 및 방법 |
US20050260112A1 (en) * | 2004-05-19 | 2005-11-24 | Hensman Carl E | Removal of elemental mercury from gas by modifying wet scrubber systems with an organic compound |
US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
US8557300B2 (en) * | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
CN101939014B (zh) * | 2007-11-15 | 2016-04-27 | 路易斯安那州大学及农业和机械学院管理委员会 | 亚硝酸盐在慢性缺血中的应用 |
JP2011507968A (ja) * | 2007-12-27 | 2011-03-10 | エイヤーズ ファーマシューティカルズ、インク. | エアロゾル化ニトライトおよび一酸化窒素供与性化合物ならびにそれらの使用 |
US8568793B2 (en) * | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
NO2451435T3 (hr) | 2009-07-08 | 2018-03-31 |
-
2010
- 2010-02-10 US US12/703,448 patent/US8568793B2/en active Active
- 2010-02-11 SI SI201031926T patent/SI2395834T1/sl unknown
- 2010-02-11 LT LT10741692T patent/LT2395834T/lt unknown
- 2010-02-11 PT PT10741692T patent/PT2395834T/pt unknown
- 2010-02-11 PL PL19177863T patent/PL3569237T3/pl unknown
- 2010-02-11 ES ES10741692T patent/ES2743303T3/es active Active
- 2010-02-11 LT LTEP19177863.8T patent/LT3569237T/lt unknown
- 2010-02-11 EP EP21161011.8A patent/EP3862007A1/en active Pending
- 2010-02-11 SI SI201032075T patent/SI3569237T1/sl unknown
- 2010-02-11 HU HUE19177863A patent/HUE055250T2/hu unknown
- 2010-02-11 AU AU2010213743A patent/AU2010213743C1/en active Active
- 2010-02-11 DK DK19177863.8T patent/DK3569237T3/da active
- 2010-02-11 HU HUE10741692 patent/HUE044781T2/hu unknown
- 2010-02-11 PT PT191778638T patent/PT3569237T/pt unknown
- 2010-02-11 ES ES19177863T patent/ES2880500T3/es active Active
- 2010-02-11 EP EP19177863.8A patent/EP3569237B1/en active Active
- 2010-02-11 DK DK10741692.7T patent/DK2395834T3/da active
- 2010-02-11 EP EP10741692.7A patent/EP2395834B1/en active Active
- 2010-02-11 PL PL10741692T patent/PL2395834T3/pl unknown
- 2010-02-11 CA CA2752129A patent/CA2752129C/en active Active
- 2010-02-11 WO PCT/US2010/023824 patent/WO2010093746A1/en active Application Filing
- 2010-02-11 JP JP2011550214A patent/JP5789519B2/ja active Active
-
2013
- 2013-10-01 US US14/042,783 patent/US8920852B2/en active Active
-
2014
- 2014-11-19 US US14/547,255 patent/US9597354B2/en active Active
- 2014-11-19 US US14/547,245 patent/US9283249B2/en active Active
-
2015
- 2015-06-22 JP JP2015124374A patent/JP6059297B2/ja active Active
-
2016
- 2016-02-08 US US15/017,772 patent/US9504709B2/en active Active
- 2016-08-29 US US15/249,746 patent/US9687505B2/en active Active
- 2016-08-30 US US15/251,015 patent/US9687506B2/en active Active
-
2017
- 2017-05-19 US US15/599,617 patent/US10251910B2/en active Active
-
2018
- 2018-05-08 US US15/973,659 patent/US10456417B2/en active Active
-
2019
- 2019-08-22 HR HRP20191516 patent/HRP20191516T1/hr unknown
- 2019-08-27 CY CY20191100910T patent/CY1121939T1/el unknown
- 2019-09-23 US US16/578,671 patent/US10874691B2/en active Active
-
2020
- 2020-04-08 US US16/842,939 patent/US10898513B2/en active Active
- 2020-12-18 US US17/126,329 patent/US11583550B2/en active Active
-
2021
- 2021-06-28 CY CY20211100571T patent/CY1124426T1/el unknown
- 2021-07-06 HR HRP20211077TT patent/HRP20211077T1/hr unknown
-
2023
- 2023-01-18 US US18/098,361 patent/US20230256006A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191516T1 (hr) | Farmaceutski pripravci koji sadrže natrij-nitrit | |
CN103272153B (zh) | 一种抑菌凝胶及其制备方法 | |
HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
JP2008509224A5 (hr) | ||
JP2010523156A5 (hr) | ||
CA2367136A1 (en) | Use of xenon for treating neurointoxications | |
CN102657611B (zh) | 丙酮酸钠鼻喷剂及其制备方法 | |
WO2009093540A1 (ja) | 二酸化塩素液剤組成物 | |
CN101120759A (zh) | 多维富硒营养强化面条 | |
CA2620123A1 (en) | Methods for treating and monitoring inflammation and redox imbalance in cystic fibrosis | |
ECSP088348A (es) | Composiciones de suplemento de hierro con tolerancia mejorada | |
EA200700979A1 (ru) | Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола | |
Harrington et al. | Effects of chlorine dioxide on thyroid function in the African green monkey and the rat | |
RU2009120115A (ru) | Фармацевтическая композиция, обладающая антипсихотической, антидепрессантной или противоэпилептической активностью, со сниженным побочным эффектом | |
RU2006129596A (ru) | Применение ксенона для коррекции патологических изменений в организме, связанных с нарушением антиоксидантного статуса | |
CN1682703A (zh) | 一种杀菌凝胶剂 | |
WO2021258654A1 (zh) | 一种银离子抑菌洗手液及其制备方法和应用 | |
HRP20160832T1 (hr) | Liječenje osteoporoze | |
Powell et al. | Acid–base and ionic fluxes in rainbow trout (Oncorhynchus mykiss) during exposure to chloramine-T | |
CN102138934B (zh) | 一种治疗疥疮的乳膏 | |
Acharya et al. | Bacteremia following placement of intracervical laminaria tents | |
CN106511377A (zh) | 一种治疗口腔疾病的组合物及其制备方法 | |
KR20190026126A (ko) | 질염 예방 및 치료용 조성물 | |
JP2007314499A (ja) | 健康ミネラル水 | |
CN107334781A (zh) | 一种用于预防和治疗口腔真菌感染的药物 |